HB-500 is a next-generation therapeutic vaccine being developed in collaboration with Gilead Sciences, Inc. (Gilead) as a potential component of ...

HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...

HOOKIPA Pharma Inc., a pharmaceutical company currently valued at $23.6 million, has initiated legal proceedings to validate ...

NEW YORK - HOOKIPA Pharma Inc. (NASDAQ: HOOK), a clinical-stage biopharmaceutical company, has announced the completion of enrollment for its Phase 1b clinical trial of HB-500, a therapeutic vaccine ...

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial. Gilead has the exclusive right to assume further development of the program thereafter.

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 ...

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United ...